Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ ...
Verywell Health3d
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer Program
Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Medical Marketing & Media3d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Fierce Pharma4d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...